Hello Heart is a digital therapeutics company focused exclusively on cardiovascular health. Their flagship product is an FDA-cleared smartphone app and connected blood pressure monitor that provides personalized insights and coaching to help people manage hypertension and other heart conditions. The app leverages AI, behavioral science, and real-world data to drive lifestyle changes like medication adherence and improved nutrition.

Co-founded in 2013 by Maayan Cohen, an experienced strategy consultant, and Ziv Meltzer, a design expert, Hello Heart was born out of their personal experiences navigating the complexities of managing chronic conditions. The founders' unique blend of healthcare, consumer behavior, and user experience expertise underpins Hello Heart's engaging and clinically-validated approach.

Looking ahead, Hello Heart aims to expand beyond hypertension management to support overall heart health, with new features like cholesterol tracking and hyperlipidemia management. The company has raised over $140 million from top-tier investors and has seen rapid growth, doubling its customer base and now serving millions of members through partnerships with major employers and health plans.

A key challenge Hello Heart faces is demonstrating sustained clinical improvements and cost savings to maintain growth in the highly competitive digital health market. Continued product innovation and real-world evidence generation will be crucial to solidifying their position as the leader in cardiovascular digital therapeutics.